title: A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients.
abstract: Tumor Associated Antigens (TAAs) are the privileged targets of almost all the cancer vaccines tested to date. Unfortunately all these vaccines failed to show a clinical efficacy. The main reason for this failure is the immune tolerance to TAAs that are self-proteins expressed by normal and cancer cells. Self-tolerance to TAAs is directed against their dominant rather than against their cryptic epitopes. The best way to overcome self-tolerance to TAAs would therefore be to target their cryptic epitopes. However, because of their low HLA-I affinity, cryptic peptides are non-immunogenic and cannot be used to stimulate an antitumor immune response unless their immunogenicity has been previously enhanced. In this paper we describe a general approach to enhance immunogenicity of almost all the HLA-B*0702 restricted cryptic peptides derived from TAAs. It consists in substituting residues at position 1 or 9 of low HLA-B*0702 affinity cryptic peptides by an Alanine or a Leucine respectively. These substitutions increase affinity of peptides for HLA-B*0702. These optimized cryptic peptides are strongly immunogenic and very importantly CTL they stimulate recognize their native counterparts.TAAs derived optimized cryptic peptides can be considered as universal antitumor vaccine since they escape self-tolerance, are immunogenic and are not patient specific.
authors: Vaxon Biotech, 75015, Paris, France.
authors: Catherine
authors: C
authors: Gallou
authors: Vaxon Biotech, 75015, Paris, France.
authors: Aude
authors: A
authors: Rougeot
authors: University Pierre-and-Marie-Curie (aka University Paris 06, INSERM U1135, CNRS ERL8255, 75013, Paris, France.
authors: Stéphanie
authors: S
authors: Graff-Dubois
authors: Vaxon Biotech, 75015, Paris, France.
authors: Kostas
authors: K
authors: Kosmatopoulos
authors: Vaxon Biotech, 75015, Paris, France.
authors: Jeanne
authors: J
authors: Menez-Jamet
mesh_terms: D000818:Animals; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000235:genetics; D001324:Autoantigens / Q000235:genetics; D019496:Cancer Vaccines / Q000276:immunology*; D019295:Computational Biology; D018984:Epitopes, T-Lymphocyte / Q000235:genetics / Q000378:metabolism*; D015793:HLA-B7 Antigen / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D010455:Peptides / Q000235:genetics; D011485:Protein Binding; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000637:transplantation
chemical_list: D000951:Antigens, Neoplasm; D001324:Autoantigens; D019496:Cancer Vaccines; D018984:Epitopes, T-Lymphocyte; C477444:HLA-B*07:02 antigen; D015793:HLA-B7 Antigen; D010455:Peptides
keywords: HLA-B7; cryptic; immunotherapy; optimized; vaccination